Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in High-Risk Endometrial Cancers
Recruiting
- Conditions
- Malignant Uterine NeoplasmUterine Corpus CarcinosarcomaEndometrial Clear Cell AdenocarcinomaEndometrial Mucinous AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Serous Adenocarcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Liquid BiopsyOther: Pap Smear
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1000
- Registration Number
- NCT05049538
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase II Study of Nivolumab with Ipilimumab and Cabozantinib in Patients with Untreated Renal Cell Carcinoma Brain Metastases
Phase 2
Recruiting
- Conditions
- Brain MetastasesRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT05048212
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR
Early Phase 1
Active, not recruiting
- Conditions
- Cervical CancerBrain Tumor
- Interventions
- Drug: 18F-FTX
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05047913
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
An Investigational Scan (MRI With Dixon Based Sequences) in Detecting Prostate Cancer
Not Applicable
Active, not recruiting
- Conditions
- Prostate Carcinoma
- Interventions
- Procedure: Dixon MRIProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT05047965
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Communication Skills to Build a Diverse Biomedical Workforce
Not Applicable
Withdrawn
- Conditions
- Behavioral Disorder
- Interventions
- Other: Communication Skills TrainingOther: Survey AdministrationOther: Educational Intervention
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 480
- Registration Number
- NCT05048290
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix
Recruiting
- Conditions
- Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type
- Interventions
- Other: Electronic Health Record ReviewOther: Laboratory Biomarker Analysis
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 70
- Registration Number
- NCT05046080
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Feasibility Study of Anatomical Modeling for Image Guided Thoracic Surgery
Not Applicable
Completed
- Conditions
- Lung Neoplasm
- Interventions
- Procedure: Computed TomographyProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT05046067
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology
Phase 2
Not yet recruiting
- Conditions
- Prostate Cancer
- Interventions
- Device: restriction spectrum imaging (RSI)
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 302
- Registration Number
- NCT05046782
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer
Phase 2
Withdrawn
- Conditions
- Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8Metastatic Lung Non-Small Cell Carcinoma
- Interventions
- Drug: Poziotinib HydrochlorideBiological: 1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05045404
Impact of Aminoglycosides in Hypotensive Septic Oncology Patients
Recruiting
- Conditions
- SepticemiaHematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
- Interventions
- Other: Electronic Health Record Review
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 319
- Registration Number
- NCT05045963
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath